Journals
MBS collaboration with University of Maine to develop antibodies to Osteopontin for breast cancer study
http://www.ncbi.nlm.nih.gov/pubmed/18237408
MBS Strep. equi clone 04D11 is used by thought leader, Dr. John Timoney for Vaccine Paper
Affects of N-terminal variation in the SeM protein of Streptococcus equi
News on Myeloperoxidase in research, MBS has new clones specific for human MPO
http://www.ncbi.nlm.nih.gov/pubmed/17592500
Press
MBS Strep. equi reagents in a rapid test for Strangles
http://www.horsetalk.co.nz/news/2010/11/078.shtml
Maine Technology Institute grant awarded to MBS collaborator Dr. Robert Causey for disease surveillance
MTI Grant Recipiants 2010
MBS has a Multipure plate of antibodies recognizing VPAC-1 recentlymaking news as a therapeutic target for patients undergoing cheomotherapy
http://www.thrombogenics.com/html/pipeline6B.asp.
Categorical meta-analysis of Osteopontin as a clinical cancer marker
MBS collaborator Lucy Liaw discusses future potential for Osteopontin work
http://www.necn.com/Boston/Health/2009/10/20/Breast-cancer-may-be-able-to/1256073734.html
Lucy Liaw discusses Additional Research
http://www.wlbz2.com/news/article/174999/9/Blood-test-may-detect-risk-for-cancer
MBS developed the murine antibody model used in the production of Aveo Pharmaceutical’s therapeutic AV-299
http://investor.aveopharma.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=1395204&highlight=
Preferred Partners
Linscott’s Directory
http://www.linscottsdirectory.com/
New England Peptide
http://www.newenglandpeptide.com/